Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Study to Characterize Patients With HER2-positive Metastatic or Locally Advanced Breast Cancer, Treated by Herceptin® as 1st Line-therapy and Without Progression for at Least 3 Years Followed by a 1-year Prospective Study for Patients Still Alive

NCT01480674 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01480674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01480674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Study to Characterize Patients With HER2-positive Metastatic or Locally Advanced Breast Cancer, Treated by Herceptin® as 1st Line-therapy and Without Progression for at Least 3 Years Followed by a 1-year Prospective Study for Patients Still Alive
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
March 28, 2011
Completion date
November 16, 2012
Enrollment
160 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer